GlaxoSmithKline plc (ADR) (GSK)

TyrVsGarm (30.62) Submitted: 7/6/2009 2:21:03 PM : Start Price: $34.24 GSK Score: -0.49

GlaxoSmithKline has two blockbusters coming off patent in 2010 which will affect the bottom line in the near-term. While GSK has a healthy pipeline, it also is sitting on over $10 Billion worth of currency (most of it in dollars). I suspect that it will try to put some (or all) of this cash to work with an acquisition (to try to further compensate for the loss of Advair and Avandia). Between acquisition costs, taxes to repatriate some of the funds, and any goodwill, I don't believe the imminent acquistion will be accretive until 2011 at the earliest.

ruinas (< 20) Submitted: 7/1/2009 4:38:44 PM : Start Price: $34.20 GSK Score: -2.76

Expect profit taking following recent run-up in market as well as FDA black box warning on anti-smoking drug Zyban/

MIKEP75731 (43.60) Submitted: 5/22/2009 3:49:00 PM : Start Price: $32.34 GSK Score: -6.28

its going to be a hard sell for them for about a year or so. and then i'll be ready for then to come back

BlindSkuirrel (70.94) Submitted: 5/8/2008 6:19:36 PM : Start Price: $40.82 GSK Score: -21.42

Rectum refuse - mgmt sucks!

Tankota (99.83) Submitted: 5/6/2008 8:37:46 AM : Start Price: $41.37 GSK Score: -21.05

TJC

delocin (< 20) Submitted: 4/28/2008 12:07:54 PM : Start Price: $41.24 GSK Score: -21.21

With risk of a Dem in office next year, and baby boomers becoming more proactive in their health, expect this stock to stay downward this year. But up as more and more baby boomers age.

Magikul (28.77) Submitted: 4/19/2008 7:21:06 AM : Start Price: $40.36 GSK Score: -22.56

the company appears stuck, no real momentum

blayson (< 20) Submitted: 4/2/2008 12:43:44 PM : Start Price: $41.16 GSK Score: -19.81

THE PRESCRIPTION DRUG INDUSTRY IS STRUGGLING, THEY ARE GETTING RID OF ALOT OF THEIR SALES FORCE AND WILL CONTINUE TO; EXPECT THIS PICK TO FLUCTUATE OVER THE NEXT YEAR AND SEE A SMALL INCREASE BUT NOT OVER MARKET

Funzer (< 20) Submitted: 11/16/2007 9:00:56 AM : Start Price: $44.56 GSK Score: -16.37

GSK is revising Avandia product label to reflect negative events such as myocardial ischemia. Since there is no reduction in cardiovascular risks for diabetics, this reduces the long term outlook for the profitablity of this drug product and GSK.

user1290 (< 20) Submitted: 1/23/2007 4:03:07 PM : Start Price: $48.21 GSK Score: -6.32

Difficulties in the form of significant patent expirations on the horizon; pipeline has still yet to actually produce anything more than promise.

Leftarmround (< 20) Submitted: 1/19/2007 6:07:30 PM : Start Price: $48.66 GSK Score: -5.56

Too many big picture constrainsts in the big pharma industry. R

OldNickel (96.56) Submitted: 12/28/2006 11:27:43 PM : Start Price: $45.89 GSK Score: -10.21

The Democrats are coming! The Democrats are coming!